The purpose of this study is to estimate the effect of high fat meal and increased gastric pH on BMS-663068 bioavailability
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Enrollment
72
BMS-663068
GSK Investigational Site
Austin, Texas, United States
Maximum observed plasma concentration (Cmax)
Time frame: Days 1-12
Area under the plasma concentration-time curve from time zero extrapolated to infinity, AUC (INF)
Time frame: Days 1-12
Safety endpoints include incidence of nonserious AEs, serious AEs, AEs leading to discontinuation
Adverse events (both serious and nonserious) will be listed and tabulated by system organ class, preferred term, and treatment.
Time frame: Days 1-12; for SAEs up to 30 days post discontinuation of dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.